Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) — The “Hemophilia Treatment Market by Type, by Drug Therapy: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to from ResearchAndMarkets.com offer.
Global Hemophilia Treatment Market was valued at USD 12,764.8 Million in 2021 and is projected to reach USD 26,905.2 Million by 2031, registering a CAGR of 7.5% from 2022 to 2031.
Hemophilia is usually an inherited bleeding disorder, in which the blood does not clot properly. This can lead to spontaneous bleeding, followed by injury or surgery. Blood contains many proteins called clotting factors, which can help stop bleeding.
People with hemophilia have low levels of factor VIII or factor IX. The severity of hemophilia a person has is determined by the amount of factor in the blood. Hemophilia is caused by a mutation, or change, in one of the genes that provides instructions for making the clotting factor proteins needed to form a blood clot.
There are two main types of hemophilia, namely hemophilia A and hemophilia B. The treatment of hemophilia involves replacing the missing blood clotting factor so that the blood can clot properly. This is done by infusion, in which commercially prepared factor concentrates are administered through a vein. People with hemophilia can learn to give these infusions themselves so that they can stop bleeding episodes, and by making the infusions regularly, they can even prevent most bleeding episodes.
Major factors driving the growth of the global hemophilia treatment market include increasing prevalence of hemophilia, technological advancements in hemophilia treatment, and supportive government initiatives in the management of hemophilia . Additionally, increasing target population, rising rate of diagnosis, and rising usage of hemophilia prophylaxis treatment are also propelling the market growth.
However, the high cost of hemophilia treatment, lack of hemophilia drugs, and serious adverse reactions associated with plasma-derived products are expected to limit the market growth. Conversely, increased awareness of hemophilia in developing countries offers lucrative opportunities for market growth.
The hemophilia treatment market is segmented on the basis of type, drug therapy, and region. Based on type, the market is segmented into Hemophilia A and Hemophilia B. Based on Pharmacotherapy, the market is segmented into Recombinant Coagulation Factor Concentrate Therapy, Plasma Derived Coagulation Factor Concentrate Therapy, Replacement Therapy non-postman and others. Regionally, it is analyzed across North America, Europe, Asia-Pacific and LAMEA.
Key companies profiled in the report are Bayer AG, Pfizer, Inc., F. Hoffmann-La Roche AG, CSL Ltd., Takeda Pharmaceuticals Company Ltd., Novo Nordisk A/S, Grifols SA, Swedish Orphan Biovitrium AB, Octapharma AG and Medexus Pharmaceuticals Inc.
- This report provides quantitative analysis of market segments, current trends, estimates and dynamics of Hemophilia Treatment Market analysis from 2021 to 2031 to identify current opportunities in the Hemophilia Treatment Market .
- Market research is offered with information related to key drivers, restraints, and opportunities.
- Porter’s Five Forces analysis highlights the ability of buyers and suppliers to enable stakeholders to make profit-driven business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the Hemophilia Treatment market segmentation helps to determine the existing market opportunities.
- Major countries in each region are mapped according to their revenue contribution in the global market.
- The positioning of market players facilitates benchmarking and provides a clear understanding of the current position of market players.
- The report includes analysis of regional and global Hemophilia Treatment market trends, key players, market segments, application areas and market growth strategies.
Main topics covered:
CHAPTER 1 INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1. Definition and scope of the market
3.2. Key findings
3.2.1. Main pockets of investment
3.3. Porter’s Five Forces Analysis
3.4. Positioning of the best player
3.5. Market dynamics
3.6.COVID-19 Market Impact Analysis
CHAPTER 4: HEMOPHILIA TREATMENT MARKET, BY TYPE
4.1.1 Market Size and Forecast
4.2 Hemophilia A
4.2.1 Key Market Trends, Growth Drivers and Opportunities
4.2.2 Market Size and Forecast, by Region
4.2.3 Market Analysis by Countries
4.3 Hemophilia B
4.3.1 Key Market Trends, Growth Drivers and Opportunities
4.3.2 Market Size and Forecast, by Region
4.3.3 Market Analysis by Countries
CHAPTER 5: HEMOPHILIA TREATMENT MARKET BY DRUGS
5.1.1 Market Size and Forecast
5.2 Treatment with recombinant coagulation factor concentrates
5.2.1 Key Market Trends, Growth Drivers and Opportunities
5.2.2 Market Size and Forecast, by Region
5.2.3 Market Analysis by Countries
5.3 Therapy with plasma-derived coagulation factor concentrates
5.3.1 Key Market Trends, Growth Drivers and Opportunities
5.3.2 Market Size and Forecast, by Region
5.3.3 Market Analysis by Countries
5.4 Non-factor replacement therapy
5.4.1 Key Market Trends, Growth Drivers and Opportunities
5.4.2 Market Size and Forecast, by Region
5.4.3 Market Analysis by Countries
5.5.1 Key Market Trends, Growth Drivers and Opportunities
5.5.2 Market Size and Forecast, by Region
5.5.3 Market Analysis by Countries
CHAPTER 6: HEMOPHILIA TREATMENT MARKET, BY REGION
CHAPTER 7: CORPORATE LANDSCAPE
7.2. The best winning strategies
7.3. Top 10 Player Product Mapping
7.4. Competitive Dashboard
7.5. Competitive heatmap
7.6. Main developments
CHAPTER 8: COMPANY PROFILES
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Company Overview
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Commercial performance
8.1.6 Key Strategic Movements and Developments
8.2 CSL Ltd. (CSL Behring)
8.2.1 Company Overview
8.2.2 Company Overview
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Commercial performance
8.2.6 Key Strategic Movements and Developments
8.3 F. Hoffmann-La Roche SA
8.3.1 Company Overview
8.3.2 Company Overview
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Commercial performance
8.3.6 Key Strategic Movements and Developments
8.4 Grifols, SA
8.4.1 Company Overview
8.4.2 Company Overview
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Commercial performance
8.4.6 Key Strategic Movements and Developments
8.5 Medexus Pharmaceuticals Inc.
8.5.1 Company Overview
8.5.2 Company Overview
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Commercial performance
8.5.6 Key Strategic Movements and Developments
8.6 Novo Nordisk A/S
8.6.1 Company Overview
8.6.2 Company Overview
8.6.3 Operating business segments
8.6.4 Product Portfolio
8.6.5 Commercial performance
8.6.6 Key Strategic Movements and Developments
8.7 octapharma sa
8.7.1 Company Overview
8.7.2 Company Overview
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Commercial performance
8.7.6 Key Strategic Movements and Developments
8.8 Pfizer Inc.
8.8.1 Company Overview
8.8.2 Company Overview
8.8.3 Operating business segments
8.8.4 Product Portfolio
8.8.5 Commercial performance
8.8.6 Key Strategic Movements and Developments
8.9 Swedish Orphan Biovitrum AB
8.9.1 Company Overview
8.9.2 Company Overview
8.9.3 Operating business segments
8.9.4 Product Portfolio
8.9.5 Commercial performance
8.9.6 Key Strategic Movements and Developments
8.10 Takeda Pharmaceuticals Company Ltd.
8.10.1 Company Overview
8.10.2 Company Overview
8.10.3 Operating business segments
8.10.4 Product Portfolio
8.10.5 Commercial performance
8.10.6 Key Strategic Movements and Developments
For more information on this report, visit https://www.researchandmarkets.com/r/fin18s